In summary, we hypothesize that the administration of ruscogenin can attenuate DSS-induced colitis by improving intestinal barrier function, reducing the inflammation response and regulating pyroptosis via TLR4/NF-κB signaling pathway. The gene discussed is TLR4; the disease is colitis.